Strategic Appointment of Professor Randolph Noelle
Lead Research Organisation:
King's College London
Department Name: Immunology Infection and Inflam Diseases
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
People |
ORCID iD |
| Randolph Noelle (Principal Investigator) |
Publications
Pino-Lagos K
(2010)
Retinoic acid: a key player in immunity.
in BioFactors (Oxford, England)
Lievens D
(2010)
Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis.
in Blood
Dalton D
(2012)
The roles of mast cells in anticancer immunity
in Cancer Immunology, Immunotherapy
Wasiuk A
(2012)
Mast cells impair the development of protective anti-tumor immunity.
in Cancer immunology, immunotherapy : CII
Guo Y
(2012)
A retinoic acid--rich tumor microenvironment provides clonal survival cues for tumor-specific CD8(+) T cells.
in Cancer research
Le Mercier I
(2014)
VISTA Regulates the Development of Protective Antitumor Immunity.
in Cancer research
Nowak EC
(2009)
Interleukin-9 and T cell subsets.
in Cell cycle (Georgetown, Tex.)
De Vries VC
(2010)
Mast cell mediators in tolerance.
in Current opinion in immunology
Wucherpfennig KW
(2011)
Autoimmune diseases have been the focus of intense research efforts.
in Current opinion in immunology
Stan RV
(2012)
The diaphragms of fenestrated endothelia: gatekeepers of vascular permeability and blood composition.
in Developmental cell
De Vries VC
(2011)
Mast cells condition dendritic cells to mediate allograft tolerance.
in Immunity
Elgueta R
(2010)
The immortality of humoral immunity.
in Immunological reviews
Nowak EC
(2010)
Interleukin-9 as a T helper type 17 cytokine.
in Immunology
Gunturu KS
(2010)
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery.
in Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Elgueta R
(2015)
CCR6-dependent positioning of memory B cells is essential for their ability to mount a recall response to antigen.
in Journal of immunology (Baltimore, Md. : 1950)
O'Connor RA
(2012)
Adjuvant immunotherapy of experimental autoimmune encephalomyelitis: immature myeloid cells expressing CXCL10 and CXCL16 attract CXCR3+CXCR6+ and myelin-specific T cells to the draining lymph nodes rather than the central nervous system.
in Journal of immunology (Baltimore, Md. : 1950)
Allie SR
(2013)
Critical role for all-trans retinoic acid for optimal effector and effector memory CD8 T cell differentiation.
in Journal of immunology (Baltimore, Md. : 1950)
Noelle R
(2010)
Cellular sources and immune functions of interleukin-9
in Nature Reviews Immunology
Lutgens E
(2010)
Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile.
in The Journal of experimental medicine
Benson MJ
(2009)
Distinction of the memory B cell response to cognate antigen versus bystander inflammatory signals.
in The Journal of experimental medicine
Nowak EC
(2012)
Tryptophan hydroxylase-1 regulates immune tolerance and inflammation.
in The Journal of experimental medicine
Wang L
(2011)
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.
in The Journal of experimental medicine
Pino-Lagos K
(2011)
A retinoic acid-dependent checkpoint in the development of CD4+ T cell-mediated immunity.
in The Journal of experimental medicine
De Vries VC
(2010)
Mast cell protease 6 is required for allograft tolerance.
in Transplantation proceedings
| Description | AICR |
| Amount | £80,000 (GBP) |
| Organisation | Association for International Cancer Research |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2013 |
| End | 02/2015 |
| Description | Cognate Interaction of B lymphocytes |
| Amount | $175,000 (USD) |
| Funding ID | R37 AI26296 |
| Organisation | National Institute of Allergy and Infectious Diseases (NIAID) |
| Sector | Public |
| Country | United States |
| Start | 03/2003 |
| End | 02/2014 |
| Description | Wellcome Trust Principal Research Fellowship - New (The cellular and molecular basis for the impact of vitamin A on immunity) |
| Amount | £4,750,000 (GBP) |
| Funding ID | 091823 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2010 |
| End | 07/2017 |
| Title | Retinoic Acid engineered mice |
| Description | We have produced mice in which retinoid acid synthesis can be manipulated. |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2013 |
| Provided To Others? | Yes |
| Impact | This mouse strain will uniquely be able to define lineages of cells that must make retinoid acid to support immunity |
| Title | VISTA antibodies and reagents |
| Description | Produced antibodies to both mouse and human VISTA and produced KO mice as well as conditional KO mice. |
| Type Of Material | Antibody |
| Year Produced | 2013 |
| Provided To Others? | Yes |
| Impact | Allows investigation of a newly described molecule that we discovered in our lab in 2011. |
| Description | Development of VISTA therapeutics |
| Organisation | Janssen Biotech, Inc. |
| Department | Oncology Discovery |
| Country | United States |
| Sector | Private |
| PI Contribution | Systems to study the activity of new therapeutic antibodies specific to VISTA |
| Collaborator Contribution | Expertise is development of fully human anti-human mabs |
| Impact | Developing fully human anti-human mabs for clinical development. |
| Start Year | 2011 |
| Description | Retinoic acid and regulatory T cell function |
| Organisation | King's College London |
| Department | Transplantation Immunology & Mucosal Biology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have provided unique genetically engineered mouse models to study regulatory T cell function |
| Collaborator Contribution | Dr Lombardi has the expertise to study regulatory T cell functions in transplantation |
| Impact | None |
| Start Year | 2013 |
| Description | Treg adoptive therapy |
| Organisation | King's College London |
| Department | MRC Centre for Transplantation |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Technology and knowledge concerning retinoic acid receptors |
| Collaborator Contribution | High level interactions with the Lombardi/Lechler LabInteractions with Lord Lab |
| Impact | Submission of a number of grant applications |
| Start Year | 2010 |
| Description | Treg adoptive therapy |
| Organisation | King's College London |
| Department | MRC Centre for Transplantation |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Technology and knowledge concerning retinoic acid receptors |
| Collaborator Contribution | High level interactions with the Lombardi/Lechler LabInteractions with Lord Lab |
| Impact | Submission of a number of grant applications |
| Start Year | 2010 |
| Description | VISTA |
| Organisation | King's College London |
| Department | MRC Centre for Transplantation |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Production of VISTA engineered proteins for future immunotherapy |
| Collaborator Contribution | Provided expertise in protein biochemistry |
| Impact | None as of yet |
| Start Year | 2010 |
| Description | VISTA Structure |
| Organisation | King's College London |
| Department | Centre for Ultrastructural Imaging |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provided VISTA proteins for structural studies |
| Collaborator Contribution | Analysis of structure of VISTA recombinant molecules |
| Impact | Involvement of pharmaceutical interest in VISTA structure. |
| Start Year | 2013 |
| Description | VISTA in inflammatory bowel disease |
| Organisation | King's College London |
| Department | Transplantation Immunology & Mucosal Biology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Produce VISTA-Ig molecules for therapy |
| Collaborator Contribution | Test VISTA-Ig molecules in murine models of inflammatory bowel disease |
| Impact | None |
| Start Year | 2013 |
| Description | VISTA in kidney disease |
| Organisation | King's College London |
| Department | Transplantation Immunology & Mucosal Biology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We produce anti-VISTA mabs and VISTA-Ig for testing in kidney disease models. |
| Collaborator Contribution | Partner is an expert in murine models of kidney disease and tests the impact of anti-VISTA and VISTA-Ig |
| Impact | none |
| Start Year | 2013 |
| Title | Compositions and Methods for Producing Adaptive Regulatory T Cells |
| Description | The present invention relates to a method for producing adaptive regulatory T cells from effector T cells by contacting the effector T cells with retinoic acid. Adaptive regulatory T cells produced by this method are Foxp3+, home to the gut, and are refractory to reversion in vivo. As such, such cells find application in the treatment of autoimmune disease and facilitating transplantation tolerance. |
| IP Reference | US2010183575 |
| Protection | Patent granted |
| Year Protection Granted | 2010 |
| Licensed | No |
| Impact | The methods described will be useful for producing stable adaptive regulatory T cells for therapy in humans with autoimmune disease and for graft rejection |
| Title | IMMUNOSTIMULATORY COMBINATIONS |
| Description | The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen. |
| IP Reference | US2011280903 |
| Protection | Patent granted |
| Year Protection Granted | 2011 |
| Licensed | Yes |
| Impact | na |
| Title | INFLAMMATION AND AUTOIMMUNE DISORDER TREATMENT USING RARa SELECTIVE AGONISTS |
| Description | The present specification provides compounds, compositions and methods using such compounds and compositions to treat an autoimmune disorder, inflammation and/or a transplant rejection. |
| IP Reference | WO2012125749 |
| Protection | Patent granted |
| Year Protection Granted | 2012 |
| Licensed | Yes |
| Impact | The present specification provides compounds, compositions and methods using such compounds and compositions to treat an autoimmune disorder, inflammation and/or a transplant rejection. |
| Title | REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF |
| Description | The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates aCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon aCD3/aGITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed |
| IP Reference | US2012195894 |
| Protection | Patent granted |
| Year Protection Granted | 2012 |
| Licensed | Yes |
| Impact | na |
| Title | REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF |
| Description | The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates aCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon aCD3/aGITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed. In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g. multiple sclerosis is disclosed |
| IP Reference | US2012301484 |
| Protection | Patent granted |
| Year Protection Granted | 2012 |
| Licensed | Yes |
| Impact | Targetting this molecule (PD-L3, VISTA) will allow enhanced immune responses to tumors and enhance tumor rejection |
| Title | Anti-VISTA Therapeutics in Oncology Licensing to JNJ Pharmaceuticals |
| Description | We have recently (Sept 2012) closed a $150 Million dollar milestone agreement with JNJ for the development of anti-VISTA mabs for the treatment of cancer. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2012 |
| Development Status | Under active development/distribution |
| Impact | It is anticipated that anti-VISTA will have profound impact on the development of anti-tumor immunity in man. |
| Title | VISTA-Ig agonists for the treatment of autoimmunity (In final negotiation of licensing to Pharma) |
| Description | VISTA-Ig represents a new class of immunosuppressive drugs. We are in the final phases of term sheet agreements with large pharma for the development of this class of drugs. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2013 |
| Development Status | Actively seeking support |
| Impact | We are currently in preclinical testing of VISTA-Ig in a variety of murine autoimmune models. Large pharma has expressed interest and we are in the final phases of licensing this new drug to pharma. |
| Company Name | ImmuNext |
| Description | In 2006 I co-founded ImmuNext and am currently CSO. The company is involved in developing biotherapeutics for autoimmunity and cancer. |
| Year Established | 2006 |
| Impact | Licensing to JNJ a new antibody based therapeutic for cancer. Licensing >$150 M in milestones plus royalties. Also in the process of licensing VISTA-Ig as a novel therapeutic for the treatment of autoimmune disease. |
| Website | http://www.immunext.com |